HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

NCT07748533 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Hemolytic Anemia (AIHA)

Interventions

DRUG: HY001N Cell Injection

Sponsor

Juventas Cell Therapy Ltd.